Evidence map›Paper›PMID 42035282›Full record

ReviewCardiovascular therapeutics2026

Integrating Traditional Wisdom With Modern Science: Ginsenosides as Antiheart Failure Agents.

Li Zhou, Yanhua Li, Wenjie Yin, Xi Gu, Jiana Shi, Fan Yang

Abstract readReview
In one paragraph

Review in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li ZhouDepartment of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0009-0621-8063
Yanhua LiDepartment of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0007-1216-1927
Wenjie YinDepartment of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0003-7889-9722
Xi GuDepartment of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0007-4618-6225
Jiana ShiCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-3422-0840
Fan YangJoint Surgery, The General Hospital of Tibet Military Region, Lhasa, Tibet, China.ORCID https://orcid.org/0009-0006-5576-4894

Funding

Kunming Medical University YQHR2025-Y10Scientific Research Fund Project of Education Department of Yunnan Province 2024J0277Yunnan Health Training Project of High Level Talents H-2025053
6 · The paper itself

Abstract

Heart failure (HF), as the terminal stage of various cardiovascular diseases, remains a global health challenge with persistently high morbidity and mortality rates. Although current therapies-including angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, and cardiac resynchronization therapy-have improved outcomes, significant limitations persist. Ginseng, a renowned traditional Chinese medicine, contains bioactive ginsenosides (e.g., Rb1, Rb3, Re, Rg1, and Rg3) that exhibit multitarget cardioprotective effects, offering a promising therapeutic strategy for HF. This review systematically elucidates the mechanisms by which ginsenosides ameliorate HF, including modulation of myocardial energy metabolism, suppression of oxidative stress and inflammation, attenuation of fibrosis, and inhibition of cardiomyocyte apoptosis. We further evaluate the synergistic efficacy of ginsenoside-containing formulations (e.g., YiQiFuMai injection and Qiliqiangxin capsule) in HF management. Although clinical evidence remains limited and heterogeneous, preclinical studies robustly support ginsenosides as pleiotropic natural compounds with therapeutic potential for HF. Future research should prioritize high-quality clinical trials, optimize delivery systems (e.g., nanocarriers), and explore combination therapies with conventional drugs to accelerate clinical translation.

Indexed as

Cardiovascular AgentsDrugs, Chinese HerbalGinsenosidesHeart FailurePanaxAnimalsAnti-Inflammatory AgentsEnergy MetabolismFibrosisHumansMyocardiumOxidative StressSignal TransductionTreatment OutcomeAnti-Inflammatory AgentsCardiovascular AgentsDrugs, Chinese HerbalGinsenosidesbiomedicalChinese traditionalginsenosidesheart failuremedicineoxidative stresstranslational scienceventricular remodeling

Identifiers

PMID42035282
PMCPMC13110372

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.